Cue Biopharma, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
CUE$18.76-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at December 31, 2024 and 2023
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $22,459 | $48,514 |
| Accounts receivable | 945 | 1,698 |
| Deposits, current portion | 929 | 287 |
| Prepaid expenses and other current assets | 805 | 955 |
| Total current assets | 25,138 | 51,454 |
| Property and equipment, net | 471 | 795 |
| Operating lease right-of-use asset | 4,370 | 6,323 |
| Deposits, net of current portion | 1,955 | 2,690 |
| Restricted cash | 152 | 151 |
| Other long term assets | 105 | 117 |
| Total assets | $32,191 | $61,530 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $2,823 | $3,501 |
| Accrued expenses | 2,908 | 4,137 |
| Research and development contract liability | 85 | 2,112 |
| Operating lease liabilities, current portion | 3,540 | 3,368 |
| Current portion of long-term debt, net | 4,333 | 3,963 |
| Total current liabilities | 13,689 | 17,081 |
| Operating lease liabilities, net of current portion | 1,003 | 3,162 |
| Long-term debt, net | — | 4,202 |
| Total liabilities | $14,692 | $24,445 |
| Commitments and contingencies (Note 14) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, authorized – 10,000,000 shares; issued and outstanding – none | — | — |
| Common stock, $0.001 par value; 200,000,000 and 100,000,000 shares authorized at December 31, 2024 and December 31, 2023, respectively; 61,819,101 shares and 47,215,116 shares issued and outstanding at December 31, 2024 and 2023, respectively | 62 | 47 |
| Additional paid-in capital | 359,301 | 338,228 |
| Accumulated deficit | (341,864) | (301,190) |
| Total stockholders’ equity | 17,499 | 37,085 |
| Total liabilities and stockholders’ equity | $32,191 | $61,530 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.